<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Erythropoiesis in response to erythropoietin (Epo) in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in vitro and in vivo is severely impaired </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the stimulative effect of c-kit ligand (KL) on the erythroid colony-forming abilities of bone marrow cells from 17 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The effects of <z:mpath ids='MPATH_458'>normal</z:mpath> donor-derived marrow were examined in comparison </plain></SENT>
<SENT sid="3" pm="."><plain>Suppression of erythroid colony formation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in response to Epo could not be restored by the addition of interleukin-3 (IL-3) to culture </plain></SENT>
<SENT sid="4" pm="."><plain>In cultures dishes supplemented with KL, erythroid colony formation was dramatically enhanced, regarding both colony number and size </plain></SENT>
<SENT sid="5" pm="."><plain>Colony-forming abilities by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors were improved following costimulation with KL, particularly in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>); however, little enhancement was apparent following KL stimulation of marrow from patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that KL responsiveness of patients with low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may still be intact, and that with progression to high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, erythroid progenitors lose proliferative reactivity to both KL and Epo stimulation </plain></SENT>
<SENT sid="7" pm="."><plain>KL may have a therapeutic role in restoring erythropoiesis in a subset of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>